Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC: Results from the Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

About 40 percent of all patients diagnosed with non-small-cell lung cancer (NSCLC) have locally advanced stage IIIA or IIIB disease. Such disease is at the borderline of anatomic resectability and associated with poor survival prospects with any present therapy. The Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group, among other North American clinical cooperative groups, have integrated radiation and chemotherapy in an attempt to prolong survival and, in some cases, cure patients with unresectable NSCLC. These two modalities have been given sequentially, concurrently, and in an alternating fashion with varying degrees of success. Trials employing cisplatin-containing chemotherapy have produced more positive results than those using other regimens, although this is not invariably so. Clearly, better treatments are needed for local and systemic disease. This paper considers possible mechanisms for combining radiation and chemotherapy, reviews the status of recent and current clinical trials, and outlines some directions for future research.

Original languageEnglish (US)
JournalCHEST
Volume103
Issue number1 SUPPL.
StatePublished - Dec 1 1992

Fingerprint

Radiation Oncology
Group Psychotherapy
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Radiotherapy
Radiation
Drug Therapy
Survival
Cisplatin
Clinical Trials
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

@article{0e3755594fce4e29909c8ad6601c35bc,
title = "Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC: Results from the Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group",
abstract = "About 40 percent of all patients diagnosed with non-small-cell lung cancer (NSCLC) have locally advanced stage IIIA or IIIB disease. Such disease is at the borderline of anatomic resectability and associated with poor survival prospects with any present therapy. The Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group, among other North American clinical cooperative groups, have integrated radiation and chemotherapy in an attempt to prolong survival and, in some cases, cure patients with unresectable NSCLC. These two modalities have been given sequentially, concurrently, and in an alternating fashion with varying degrees of success. Trials employing cisplatin-containing chemotherapy have produced more positive results than those using other regimens, although this is not invariably so. Clearly, better treatments are needed for local and systemic disease. This paper considers possible mechanisms for combining radiation and chemotherapy, reviews the status of recent and current clinical trials, and outlines some directions for future research.",
author = "{Wagner Jr.}, Henry",
year = "1992",
month = "12",
day = "1",
language = "English (US)",
volume = "103",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Rational integration of radiation and chemotherapy in patients with unresectable stage IIIA or IIIB NSCLC

T2 - Results from the Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group

AU - Wagner Jr., Henry

PY - 1992/12/1

Y1 - 1992/12/1

N2 - About 40 percent of all patients diagnosed with non-small-cell lung cancer (NSCLC) have locally advanced stage IIIA or IIIB disease. Such disease is at the borderline of anatomic resectability and associated with poor survival prospects with any present therapy. The Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group, among other North American clinical cooperative groups, have integrated radiation and chemotherapy in an attempt to prolong survival and, in some cases, cure patients with unresectable NSCLC. These two modalities have been given sequentially, concurrently, and in an alternating fashion with varying degrees of success. Trials employing cisplatin-containing chemotherapy have produced more positive results than those using other regimens, although this is not invariably so. Clearly, better treatments are needed for local and systemic disease. This paper considers possible mechanisms for combining radiation and chemotherapy, reviews the status of recent and current clinical trials, and outlines some directions for future research.

AB - About 40 percent of all patients diagnosed with non-small-cell lung cancer (NSCLC) have locally advanced stage IIIA or IIIB disease. Such disease is at the borderline of anatomic resectability and associated with poor survival prospects with any present therapy. The Lung Cancer Study Group, Eastern Cooperative Oncology Group, and Radiation Therapy Oncology Group, among other North American clinical cooperative groups, have integrated radiation and chemotherapy in an attempt to prolong survival and, in some cases, cure patients with unresectable NSCLC. These two modalities have been given sequentially, concurrently, and in an alternating fashion with varying degrees of success. Trials employing cisplatin-containing chemotherapy have produced more positive results than those using other regimens, although this is not invariably so. Clearly, better treatments are needed for local and systemic disease. This paper considers possible mechanisms for combining radiation and chemotherapy, reviews the status of recent and current clinical trials, and outlines some directions for future research.

UR - http://www.scopus.com/inward/record.url?scp=0027093440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027093440&partnerID=8YFLogxK

M3 - Article

C2 - 8380132

AN - SCOPUS:0027093440

VL - 103

JO - Chest

JF - Chest

SN - 0012-3692

IS - 1 SUPPL.

ER -